Traws Pharma Shares Surge 83% on Development of Bird Flu Treatment

Dow Jones

2024-12-23

By Denny Jacob

Traws Pharma shares surged 83% after the company disclosed progress in the development of tivoxavir marboxil as a treatment for HSN1 bird flu.

Shares jumped to $9.16. The stock is down 73% on the year.

The clinical-stage biopharmaceutical company said current topline data from a Phase 1 trial showed that a single dose of the treatment maintained plasma drug levels consistently above EC(90) for more than 23 days with higher dose dating coming.

"This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza," said Chief Science Officer C. David Pauza.

Bird flu is once again an issue to watch. California last week declared a state of emergency due to an increased number of H5N1 bird flu cases that have been detected in the state's dairy cows.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 23, 2024 08:28 ET (13:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2493757059"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493757059\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2493757059?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493757059","market":"hk","top_or_hot":-1,"title":"Traws Pharma Shares Surge 83% on Development of Bird Flu Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<p>\n  Traws Pharma shares surged 83% after the company disclosed progress in the development of tivoxavir marboxil as a treatment for HSN1 bird flu. \n</p>\n<p>\n  Shares jumped to $9.16. The stock is down 73% on the year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said current topline data from a Phase 1 trial showed that a single dose of the treatment maintained plasma drug levels consistently above EC(90) for more than 23 days with higher dose dating coming. \n</p>\n<p>\n  \"This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza,\" said Chief Science Officer C. David Pauza. \n</p>\n<p>\n  Bird flu is once again an issue to watch. California last week declared a state of emergency due to an increased number of H5N1 bird flu cases that have been detected in the state's dairy cows. \n</p>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2024 08:28 ET (13:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Shares Surge 83% on Development of Bird Flu Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Shares Surge 83% on Development of Bird Flu Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-23 21:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Denny Jacob \n</p>\n<p>\n  Traws Pharma shares surged 83% after the company disclosed progress in the development of tivoxavir marboxil as a treatment for HSN1 bird flu. \n</p>\n<p>\n  Shares jumped to $9.16. The stock is down 73% on the year. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said current topline data from a Phase 1 trial showed that a single dose of the treatment maintained plasma drug levels consistently above EC(90) for more than 23 days with higher dose dating coming. \n</p>\n<p>\n  \"This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza,\" said Chief Science Officer C. David Pauza. \n</p>\n<p>\n  Bird flu is once again an issue to watch. California last week declared a state of emergency due to an increased number of H5N1 bird flu cases that have been detected in the state's dairy cows. \n</p>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 23, 2024 08:28 ET (13:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRAW","symbol_name":"TRAWS PHARMA","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2493757059","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493757059","pubTimestamp":1734960480,"columns":[{"name":"行業數據","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Traws Pharma shares surged 83% after the company disclosed progress in the development of tivoxavir marboxil as a treatment for HSN1 bird flu.Shares jumped to $9.16. The stock is down 73% on the year.The clinical-stage biopharmaceutical company said current topline data from a Phase 1 trial showed that a single dose of the treatment maintained plasma drug levels consistently above EC for more than 23 days with higher dose dating coming.\"This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza,\" said Chief Science Officer C. David Pauza.Bird flu is once again an issue to watch. California last week declared a state of emergency due to an increased number of H5N1 bird flu cases that have been detected in the state's dairy cows.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRAW":"TRAWS PHARMA","BK4007":"制药"},"translate_title":"Traws Pharma股价因禽流感治疗方法的开发而飙升83%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":0.9},"content_text":"By Denny Jacob \n\n\n  Traws Pharma shares surged 83% after the company disclosed progress in the development of tivoxavir marboxil as a treatment for HSN1 bird flu. \n\n\n  Shares jumped to $9.16. The stock is down 73% on the year. \n\n\n  The clinical-stage biopharmaceutical company said current topline data from a Phase 1 trial showed that a single dose of the treatment maintained plasma drug levels consistently above EC(90) for more than 23 days with higher dose dating coming. \n\n\n  \"This result is highly encouraging for future clinical development of tivoxavir marboxil for treating human H5N1 influenza,\" said Chief Science Officer C. David Pauza. \n\n\n  Bird flu is once again an issue to watch. California last week declared a state of emergency due to an increased number of H5N1 bird flu cases that have been detected in the state's dairy cows. \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2024 08:28 ET (13:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}